Choline PET/CT in parathyroid imaging

Broos, Wouter A M; Zant, Friso M. van der; Knol, Remco J.J.; Wondergem, Maurits

doi:10.1097/mnm.0000000000000952

Cited by 61 publications

(48 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only Rep et al [25] reported scanning patients 3 times, at 5, 60 and 120 min after FCH injection. The FCH dosage was fixed in 16 studies, in the range of 100-230 MBq [15,[19][20][21][22][23][24][25][26][27][28][31][32][33][34]; it was adjusted to the patient's body weight in 5 (1.5-3.2 MBq/kg) and not declared in two studies [12,16,17,29,30].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

18F-choline PET/CT and PET/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature

et al. 2020

View full text Add to dashboard Cite

The aims of the present systematic review were to: (1) assess the role of 18 F-fluorocholine (FCH) positron emission tomography (PET) with computed tomography (CT) and PET with magnetic resonance imaging (MRI) in patients with biochemically known hyperparathyroidism; (2) compare the diagnostic performance of FCH PET/CT or PET/MRI with conventional morphological and functional imaging. A literature search until December 2019 was performed in the PubMed, Scopus and Web of Science databases, using the terms "choline" AND "PET" AND "hyperparathyroidism". The search was conducted with and without the addition of filters (e.g., language: English only; type of article: original article; subjects: humans only) and selecting only articles published in the last 5 years. Twenty-three articles and 1112 patients were considered. Different FCH PET/CT acquisition protocols were adopted across the studies, using dynamic, early or delayed scans. FCH PET/CT proved more accurate than ultrasonography (US) or 99mTc-sestamibi single-photon emission tomography (SPET). PET/ MRI also seemed to be more accurate than MRI alone in detecting benign parathyroid lesions. FCH PET/CT is more accurate than conventional morphological and functional imaging modalities (US or SPET) for the detection of benign parathyroid lesions. It could, therefore, be a reliable tool in both primary and recurrent hyperparathyroidism.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Comparisons between FCH PET/CT and 99mTc-MIBI SPET/CT with a dual-phase and/or subtraction protocol were reported in numerous studies (Table 2; [4,[12][13][14][15][16][17][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34]).…”

Section: Resultsmentioning

confidence: 99%

18F-choline PET/CT and PET/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Im Rahmen einer umfassenden Metaanalyse ergab sich eine gepoolte Detektionsrate von 94 % [21]. Einen Überblick über die mittels 18 F-Cholin-; 11 C-Cholin-und 11 C-Methionin-PET/CT erreichten Sensitivitäten und Detektionsraten [22] liefert ▶ Tab. 1.…”

Section: Ergebnisse Literaturunclassified

“…Dabei werden 370 -1100 MBq des Radiopharmakons intravenös appliziert und die Bildakquise sofort oder mit einem Zeitversatz bis zu 40 Hals bis zumindest Unterrand der Leber) 30 bis 60 Minuten post injektionem zusammen. Dabei beträgt die Aufnahmezeit im Regelfall 3 Minuten pro Bettposition[22]. Die Auswertung erfolgt visuell und semiquantitativ (SUV max ).…”

unclassified

Lokalisationsdiagnostik von Nebenschilddrüsenadenomen mittels PET/CT

Odparlik

Hering

2020

Der Nuklearmediziner

View full text Add to dashboard Cite

ZusammenfassungDie häufigste Ursache eines primären Hyperparathyreoidismus ist ein funktionell relevantes Nebenschilddrüsenadenom, welches meist solitär, teils jedoch auch ektop vorkommen kann. In Vorbereitung der kausalen Therapie, dem operativen Vorgehen, ist eine exakte Lokalisationsdiagnostik essenziell um den Eingriff genau zu planen und so wenig traumatisch wie möglich zu gestalten. Dadurch kann die Häufigkeit von Komplikationen wie postoperativem Hypoparathyreoidismus, aber z. B. auch einer Recurrensparese deutlich vermindert werden. In der Regeldiagnostik kommen zervikaler Ultraschall, MRT und 99 mTc-MIBI-Szintigrafie zur Anwendung. Bei fehlendem oder uneindeutigem Befund kann eine ergänzende PET-Diagnostik (18F-Cholin; 11C-Cholin; 11C-Methionin) erfolgen, wodurch häufig doch noch eine Lokalisierung gelingt. Im Vergleich zum Einsatz von Subtraktionsszintigrafie und SPECT/CT wird für den Einsatz der PET/CT zudem eine niedrigere Strahlenexposition für die Patienten beschrieben.

show abstract

“…A téma fontosságát és aktualitását az is mutatja, hogy az elmúlt években és napjainkban is számos hazai és nemzetközi kutatás vizsgálja a PET/CT, PET/MRI szerepét a klinikai N-és M-stádium meghatározásában, vagyis hogy a hagyományos képalkotó eljárásokhoz ké-pest (CT, MRI) milyen hozzáadott értékekkel, többletinformációval bírnak, és ez mennyiben járul hozzá az eltervezett kezelési stratégiák közötti, illetve azokon belüli változtatáshoz [13][14][15]. A PET-képalkotás segítségével az élő szervezetben zajló biológiai folyamatok mérhetővé válnak (metabolikus aktivitás, a daganatszövet legmalignusabb részei, tumorhatárok stb.…”

Section: Eredeti Közleményunclassified

A PET/CT szerepe a sugárkezelésre kerülő betegek N és M klinikai stagingjében, a terápia meghatározásában. Intézeti tapasztalatok

et al. 2018

View full text Add to dashboard Cite

Introduction and aim: The aim of our study was to investigate changes in clinical staging N (lymph node) and M (distant metastasis) in patients who receive PET/CT-based 3D radiotherapy within complex oncological treatment, and compare to conventional cross-sectional imaging staging technique. We also investigated the presence of PET/CT-detected second tumors and the effect of PET/CT on therapeutic decisions. Method: From the 1st of January 2015 to the 30th of November 2016, 192 patients (n = 192) were treated with PET/CT-based radiation (109 head, 44 lung, 28 rectum and 11 cervical localization) in the Oncoradiology Institute of the Health Center of the University of Kaposvár. All patients received conventional cross-sectional and PET/CT imaging in accordance with the valid investigation protocol. The average time interval between the two cross-sectional investigations was 5.2 weeks. Clinical N and M staging was performed on the basis of the classification of the American Joint Committee on Cancer (AJCC) and the Union of International Cancer Control (UICC). Results: By analyzing the clinical stages N and M separately, based on the results of the PET/CT studies, the N stage was changed in 77 cases and the M stage changed in 31 cases. Overall, the PET/CT study resulted in higher clinical stages in 68 (35.4%) patients and lower clinical stages in 14 (7.3%) patients. The treatment plan was changed in 9% of the patients (n = 18) (definitive versus palliative treatment) and the extension of radiotherapy treatment target volume (PTV) was indicated in 20% of the patients (n = 39) due to the change in clinical lymph node status. PET/CT also detected secondary tumors in 15 (8%) patients. Conclusion: Based on our results, the addition of PET/CT to conventional cross-sectional staging imaging permits a more accurate clinical classification of N and M stages and significantly influences therapeutic decisions. PET/CT imaging also provides a great help in detecting occult second tumors. The results of our Institute harmonize with the international data available in the literature. Orv Hetil. 2018; 159(39): 1593–1601.

show abstract

Choline PET/CT in parathyroid imaging

Cited by 61 publications

References 54 publications

18F-choline PET/CT and PET/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature

18F-choline PET/CT and PET/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature

Lokalisationsdiagnostik von Nebenschilddrüsenadenomen mittels PET/CT

A PET/CT szerepe a sugárkezelésre kerülő betegek N és M klinikai stagingjében, a terápia meghatározásában. Intézeti tapasztalatok

Contact Info

Product

Resources

About